Pentasa

Description

The drug Pentasa has an anti-inflammatory effect, used to treat Crohn’s disease and ulcerative colitis.
It has a local anti-inflammatory effect due to inhibition of the activity of neutrophil lipoxygenase and the synthesis of prostaglandins and leukotrienes. Slows down migration, degranulation, phagocytosis of neutrophils, as well as the secretion of immunoglobulins by lymphocytes.
It has an antibacterial effect against E. coli and some cocci (manifests in the colon).
It has an antioxidant effect (due to the ability to bind to free oxygen radicals and destroy them).
Reduces the risk of relapse in Crohn’s disease, especially in patients with ileitis with a long duration of the disease.
The therapeutic effect of mesalazine occurs as a result of local contact of the drug with the intestinal mucosa. After oral administration, the tablet disintegrates into microgranules, which act as independent forms of the drug with a slow release of mesalazine. This ensures the therapeutic effect of the drug from the duodenum to the rectum at any pH value. The microgranules reach the duodenum within the first hour after taking the tablet. The passage of the drug through the intact small intestine when taken orally is carried out within 3-4 hours.
Active ingredient: Mesalazine

Prescription medicine.